NYSE: MRSH · Insurance Brokers
Marsh & McLennan Companies (MRSH) fair value: undervalued or overvalued?
As of 31 Oct 2026, Faircurve's model values Marsh & McLennan Companies (MRSH) at $201.24 a share. The stock last closed at $203.63, which puts the model's fair value 1.2% below the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 3 Nov 2026. Marsh & McLennan Companies, Inc.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 31 Oct 2026 moved the fair value from $198.28 to $201.24 (+1.5%). The stock's own trading multiple rose with its price, and the fair value follows it in part: most of the move.
What the model makes of itThe price of $203.63 is 1.2% above it: Fairly valued, on a medium evidence grade.
What's nextNext report on 4 Feb 2027. Options prices imply a move of about 7% either way over the next month. The next weekly run is on Saturday 7 Nov 2026.
What price range does the model give MRSH?
The calibrated range for MRSH over 63 trading days is $188.74 to $223.55. It sits around the last close, and its width comes from the volatility that MRSH's own options imply (26% a year), calibrated weekly against realised prices (n = 6,661 past valuations, refreshed 31 Oct 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $151.28 to $261.18. In 50% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 31 Oct 2026
Marsh & McLennan Companies, Inc. (MRSH) is a leading professional services organisation in financial services. It delivers expert guidance across risk management, strategic planning and human capital.
Faircurve's model put the fair value at $201.24 a share on 31 Oct 2026, the midpoint of 2,000 simulations. That is up from $198.28 on the previous run, a move of +1.5%. In the model's own words, the stock's own trading multiple rose with its price, and the fair value follows it in part: most of the move. The calibrated range over 63 trading days is $188.74 to $223.55. Ranges built this way held the price 60% of the time at this horizon, across 6,661 past valuations. The model grades the evidence Medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.
On quality, the company scores 64 out of 100 against comparable companies, the model's composite of six factors. Stability scores 99, with five-year EBITDA margin downside volatility of 0.8 pts against a peer median of 2.6 pts. Capital discipline scores 83, with net buybacks at 3.0% of market value against a peer median of 0.9%. Balance sheet scores 40, with net debt to EBITDA of 3.41x against a peer median of 3.16x. The model compares the company with Arthur J. Gallagher & Co. (AJG), Aon plc (AON), Brown & Brown, Inc. (BRO), Ryan Specialty Holdings, Inc. (RYAN) and CorVel Corporation (CRVL). Willis Towers Watson Public Limited Company (WTW) and Goosehead Insurance, Inc (GSHD) are also compared, but the model gives them no result on this date.
Written from the figures on this page for the 31 Oct 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does MRSH report earnings, and how has the stock reacted?
Marsh & McLennan Companies's next earnings report is scheduled for 4 Feb 2027. Companies can move their dates.
Options prices on 3 Nov 2026 imply a move of about 7.1% in either direction through the nearest expiry, about 44 days out. That is the size the market is pricing, not a direction. MRSH's 30 day implied volatility works out to about 7.4% over one month.
On 4 Nov 2026 MRSH moved 3.3% in one session, against the 1.6% a day that options had priced: 2.1 times the implied size.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across MRSH's last 8 reports, ignoring direction, was 4.5%.
What the options market has priced for a month's move in MRSH
How does MRSH score on business quality?
Marsh & McLennan Companies's overall quality score is 64 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 58 | 13.2%ROIC | 12.5% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 69 | 1.03xFCF / net income | 1.08x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 53 | 10.3%Revenue growth, trailing | 15.1% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 83 | 3.0%Net buybacks / market value | 0.9% |
| Balance sheetNet debt to EBITDA and interest coverage. | 40 | 3.41xNet debt / EBITDA | 3.16x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 99 | 0.8 ptsEBITDA margin downside volatility, 5y | 2.6 pts |
How does MRSH compare with similar companies?
The companies in insurance brokers closest to Marsh & McLennan Companies in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| AJG Arthur J. Gallagher & Co. | $273.45 | $279.37 | +2.2% | Fairly valued |
| AON Aon plc | $330.16 | $312.94 | -5.2% | Fairly valued |
| WTW Willis Towers Watson Public Limited Company | $327.66 | $354.17 | +8.1% | Low evidence grade |
| BRO Brown & Brown, Inc. | $70.92 | $73.28 | +3.3% | Fairly valued |
| RYAN Ryan Specialty Holdings, Inc. | $45.73 | $56.56 | +23.7% | Undervalued |
| CRVL CorVel Corporation | $82.64 | $81.64 | -1.2% | Fairly valued |
| GSHD Goosehead Insurance, Inc | $52.23 | $47.27 | -9.5% | Low evidence grade |
What the comparable companies' multiples alone would give for MRSH, the peer-implied price, is $203.45 a share on this run. The fair value weighs that against the company's own multiple.
Marsh & McLennan Companies at a glance
Marsh & McLennan Companies, Inc. (MRSH) functions as a leading professional services organization, delivering expert guidance and innovative solutions to clients across the vital domains of risk management, strategic planning, and human capital.
- Market value
- $95.7B
- Sector
- Financial Services
- Industry
- Insurance Brokers
- Revenue expected, next twelve months
- $30.0B
- Consensus revenue growth, next fiscal year
- +6.6%
- Analysts with estimates
- 14
- Beta to the US market
- -0.25
- First valued by Faircurve
- 4 Jul 2026
At the close of 3 Nov 2026, 52.1% of the 1,081 graded US stocks the model covers traded below the model's fair value. MRSH was not among them.
How the fair value is worked out: the model prices Marsh & McLennan Companies on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 24 Oct 2026 the model's fair value for MRSH was $198.28. As of 31 Oct 2026 it is $201.24, a change of +1.5%. The stock's own trading multiple rose with its price, and the fair value follows it in part: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Marsh & McLennan Companies's valuation
Is Marsh & McLennan Companies stock undervalued or overvalued?
On Faircurve's model, MRSH reads as Fairly valued as of 31 Oct 2026. The model's fair value is $201.24 a share against a last close of $203.63, a gap of -1.2%.
What is MRSH's fair value?
$201.24 a share as of 31 Oct 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $151.28 to $261.18.
What price range does the model give MRSH?
$188.74 to $223.55 over 63 trading days. Ranges built this way held the price 60% of the time across 6,661 past valuations, refreshed 31 Oct 2026.
When does Marsh & McLennan Companies report earnings next?
The next report is scheduled for 4 Feb 2027. Companies can move their dates.
How much has MRSH moved on past earnings reports?
Across its last 8 reports the median two session move was 4.5%, ignoring direction. The largest was -8.3% around the report of 17 Apr 2025.
How confident is the model in this valuation?
The model's evidence grade for MRSH is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on MRSH
The model holds no idea open on MRSH today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on MRSH with their outcomes. A free account is enough.